News | October 28, 2021
Indian Pharma Market witnesses rise in volumes and prices in September.
Acute therapies continue to report strong growth compared to chronic ones.
Acute therapies continue to report strong growth compared to chronic ones.
The interim analysis showed that the MVC-COV1901 vaccine has a good safety profile and elicits promising neutralising antibody titres
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
The injection is used to reverse the effects of the muscle relaxants given to patients during surgery
More than 90,000 patients utilise the services daily
The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all
The BLA is being submitted under the accelerated approval pathway and is primarily based on clinical, biomarker and safety data from the Phase 2b clinical trial in people with early AD and confirmed amyloid pathology
Post normalisation of high growth months of April and May this year the average IPM growth from June to August this year stood at 15.2 % YoY : Ind-Ra reports
Ampion is directly administered by inhalation and it allows the drug to directly target and attenuate inflammation in the lungs
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
Subscribe To Our Newsletter & Stay Updated
